Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: A systematic review of randomized controlled trials

American Journal of Transplantation

Volumn 12, Issue 10, 2012, Pages 2601-2607

  Goralczyk, A D ^a   Bari, N ^a   Abu Ajaj, W ^a   Lorf, T ^a   Ramadori, G ^a   Friede, T ^a   Obed, A ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Acute kidney injury; arterial hypertension; chronic renal failure; diabetes

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FOLLOW UP; HUMAN; KIDNEY FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

CALCINEURIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84867098664     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04157.x     Document Type: Review

References (35)

1. Ojo AO, Held PJ, Port FK, et al,. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
2. McCauley J, Van Thiel DH, Starzl TE, Puschett JB,. Acute and chronic renal failure in liver transplantation. Nephron 1990; 55: 121-128.
3. Chapman JR,. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 2011; 11: 693-697.
4. Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B,. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998; 49: 356-363.
5. Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE,. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl 2000; 6: 521-530.
6. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL,. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: A meta-analysis. Am J Transplant 2006; 6: 1578-1585.
7. Farkas SA, Schnitzbauer AA, Kirchner G, Obed A, Banas B, Schlitt HJ,. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int 2009; 22: 49-60.
8. Goralczyk AD, Hauke N, Bari N, Lorf T, Obed A,. Interleukin 2 receptor antagonists for liver transplant recipients: A systematic review and meta-analysis of controlled studies. Hepatology 2011; 54: 541-554.
9. Asrani SK, Leise MD, West CP, et al,. Use of sirolimus in liver transplant recipients with renal insufficiency: A systematic review and meta-analysis. Hepatology 2010; 52: 1360-1370.
10. Mele TS, Halloran PF,. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000; 47: 215-245.
11. Allison AC, Eugui EM,. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
12. Moore J, Middleton L, Cockwell P, et al,. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta-analysis. Transplantation 2009; 87: 591-605.
13. Wiesner R, Rabkin J, Klintmalm G, et al,. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442-450.
14. OPTN/SRTR Annual Report 2010. Available from: http://www.ustransplant. org/annual-reports/current/
15. Sharma P, Schaubel DE, Guidinger MK, Goodrich NP, Ojo AO, Merion RM,. Impact of MELD-based allocation on end-stage renal disease after liver transplantation. Am J Transplant 2011; 11: 2372-2378.
16. Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2009.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470.
18. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
19. Deeks J, Altman D, Bradburn M,. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In:, Egger M, Smith G, Altman D, eds. Meta-Analysis in Context. London: BMJ Books; 285-311; 2001.
20. Viechtbauer W,. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software 2010; 36.
21. Cox DR,. The continuity correction. Biometrika 1970; 57: 217-219.
22. Friedrich JO, Adhikari NK, Bayene J,. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007. 7: 5.
23. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
24. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. ISBN 3-900051-07-0, URL http://www.R-project.org/
25. Beckebaum S, Klein CG, Sotiropoulos GC, et al,. Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: Clinical results of a prospective randomized study. Transplant Proc 2009; 41: 2567-2569.
26. Berlakovich G, Windhager T, Wamser P, et al,. Limits of MMF in liver transplantation-discontinuation of a CYA withdrawal trial [abstract]. Second joint AST/ASTS meeting 2001.
27. Pageaux G-P, Rostaing L, Calmus Y, et al,. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006; 12: 1755-1760.
28. Schlitt HJ, Barkmann A, Böker KH, et al,. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. The Lancet 2001; 357: 587-591.
29. Schmeding M, Kiessling A, Neuhaus R, et al,. Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial. Transplantation 2011; 92: 923-929.
30. Stewart SF, Hudson M, Talbot D, Manas D, Day CP,. Mycophenolate mofetil monotherapy in liver transplantation. The Lancet 2001; 357: 609-610.
31. Boudjema K, Camus C, Saliba F, et al,. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: A randomized study. Am J Transplant 2011; 11: 965-976.
32. Neuberger JM, Mamelok RD, Neuhaus P, et al,. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: The "ReSpECT" study. Am J Transplant 2009; 9: 327-336.
33. Jain A, Kashayap R, Demetris A, Eghstesad B, Pakharna R, Fung JJ,. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8: 40-46
34. Anand AC, Hubscher SG, Gunson BK, McMaster P, Neuberger JM,. Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation 1995; 60: 1098-103.
35. Marquet P,. The MONOCEPT study. Interruption of the calcineurin inhibitors (CNI) and introduction of mycophenolate mofetil (MPA) in liver transplant patients with side effects due to CNI: Study of the reduction of the risks of rejection by MPA therapeutic drug monitoring. Clinicaltrials.gov identifier NCT00456235.